IPN60340 (ICT01)
1st-line unfit Acute Myeloid Leukemia (AML)
Phase 2/3Breakthrough Therapy Designation granted
Key Facts
Indication
1st-line unfit Acute Myeloid Leukemia (AML)
Phase
Phase 2/3
Status
Breakthrough Therapy Designation granted
Company
About Ipsen
Ipsen is a global specialty-care biopharmaceutical company with a focused mission to develop and commercialize innovative medicines in oncology, rare diseases, and neuroscience. Under CEO David Loew, the company has achieved strong commercial execution, delivering over 9% sales growth in 2024 and upgrading guidance in 2025, underpinned by a robust balance sheet and investment-grade credit ratings. Its strategy centers on deep therapeutic area specialization, a balanced internal and external innovation model, and leveraging its unique toxin platform to build a sustainable, high-growth pipeline.
View full company profile